| Autor: |
Canterbury, Laura, Adekanmbi, Idowu J. |
| Předmět: |
|
| Zdroj: |
Canadian Journal of Pathology; 2018 Supplement, Vol. 10, p54-55, 2p, 1 Color Photograph |
| Abstrakt: |
Introduction: Scedosporium are ubiquitous filamentous fungi present in soil, sewage and polluted waters1. Known species includes; S.boydii, S.apiospermum and S.auratiacum. Among wide spectrum of conditions caused by Scedosporium are; airway colonization, sinopulmonary infections, extrapulmonary infections, mycetoma and disseminated diseases1,2,3. Scedosporium causes resistant life-threatening infection commonly in immunocompromised hosts with associated with high mortality rate in lung transplant patients4. We report a case of persistent scedosporium infection, 10 years post-transplant in a 74-year-old male. Case Report: 74-year-old male presented with increased cough and sputum and increase work of breeding. Pulmonary functions test shows decrease in FVC with evidence of airflow obstruction. Chest X-ray shows cavitary lesion in the left upper lobe as well as tree in bud appearing changes. Initial fungal culture of bronchial washing reveals presence of scedosporium species. He was started on posaconazole. Subsequent CT chest although stable continue to demonstrate thick walled cavitary lesions. Bronchial wash for cytology was received five months after initiation of antifungal. Conclusion: Scedosporium is an opportunistic fungal pathogen that is increasingly becoming a cause of serious infection in severely ill or immunocompromised patients especially in solid organ transplant. Two members of this genus; S.apiospermum and S.prolificans are the major pathogens in humans1. Septate hyphae bearing conidiophores and flask shaped annelides with background inflammation or granulomata is an important clue1.Identification of scedosporium is of clinical importance as this organism compared to other pathogenic fungi is resistant to Amphoterin B and some Azoles3,4. The mortality rate among organ transplant recipients is about 50%5. Efficacy rate with Voriconazole is only 30% and utility of combination therapy in the treatment of scedosporidiosis is unknown2,5. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
